Profusa Inc. has entered into a know-how agreement with the Mayo Clinic to develop and market high-impact clinical applications of Profusa’s oxygen monitoring technologies. 

Potential target indications for these potential products include cardiovascular, renal, multi-organ, and orthopedic applications, among others, where intra-organ postoperative perfusion monitoring can potentially improve clinical outcomes. The collaboration also supports Profusa’s potential commercialization of Lumee oxygen sensing and tissue monitoring technology for chronic limb-threatening ischemia (CLTI) in the United States.

“Following more than a decade of development and over $100 million in investment, our Lumee technology enables continuous, real-time measurement of tissue oxygen directly within the body, which we believe to be a first-of-its-kind, disruptive biochemistry monitoring platform,” Profusa Chairman/CEO Ben Hwang, Ph.D., said. “In addition, we are committed to continuing to harness our platform technology for innovative solutions that seek to both address large unmet clinical needs and reduce costs for healthcare systems through earlier detection and improved disease management. We look forward to collaborating with Mayo Clinic for the U.S. commercialization of Lumee for chronic limb-threatening ischemia and developing products to address new indications to expand our oxygen tissue monitoring technology’s market and therapeutic reach.”

Michael Kendrick, M.D., Chair of the Department of Surgery at Mayo Clinic, Rochester, Minn., added, “Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure. Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue.”

Based in Berkeley, Calif., Profusa is a commercial stage digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable, and affordable biosensors and its intelligent data platform, Profusa aims to provide patients with a personalized biochemical signature rooted in data.